<DOC>
	<DOCNO>NCT02678052</DOCNO>
	<brief_summary>The purpose study assess prevalence major structural birth defect infant female participant ulcerative colitis ( UC ) Crohn 's disease ( CD ) expose vedolizumab pregnancy , compare participant UC CD expose biologic agent .</brief_summary>
	<brief_title>OTIS Vedolizumab Pregnancy Exposure Registry</brief_title>
	<detailed_description>The drug observe study call Vedolizumab . Vedolizumab approve treatment adult participant moderately severely active UC CD achieve inadequate response , loss response , intolerant conventional and/or biologic treatment . This study look possible association vedolizumab pregnancy outcome , include health mother , fetus , infant female plan unplanned pregnancy least 1 dose expose time last menstrual period ( LMP ) pregnancy vedolizumab ( Entyvio ) biological agent UC CD . The study enroll approximately 200 pregnant female participant draw 3 source : OTIS Network , pregnant woman spontaneously contact study research center sponsor refer health care practitioner ( HCP ) North America woman North America become pregnant participate Entyvio clinical study undertake sponsor . Participants assign one two cohort : - No chronic disease prospective cohort - UC/CD prospective cohort All participant observe throughout study . All participant ask record medication ( include dose , frequency , route ) , additional exposure event pregnancy progress pregnancy diary . This multi-center trial conduct worldwide . The overall time participate study 6 year . Cohort enrollment do 20 week gestation period intake interview would schedule telephonically . Schedule intake interview participant depend upon duration LMP prior enrollment participant study . Outcome interview would conduct within 0 6 week delivery , dysmorphological examination live infant would conduct within 0 12 month delivery pediatric medical record review questionnaire would hold 1 year delivery .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<criteria>For UC/CD Prospective Cohort : 1 . Is currently pregnant woman UC CD , 2 . Has exposure Entyvio biologic agent dose , time first day LMP , 3 . Has enrol later 19 complete week LMP . 4 . Agrees condition requirement study include interview schedule , release medical record , physical examination live bear infant . For 'no chronic disease ' Prospective Cohort : 5 . Is currently pregnant woman chronic disease . 6 . Has exposure biological agent time first day LMP , 7 . Has enrol later 19 complete week LMP . 8 . Agrees condition requirement study include interview schedule , release medical record , physical examination live bear infant . For UC/CD Prospective Cohort : 1 . Is great ( &gt; ) 19 complete week gestation prior enrollment , 2 . Has first contact OTIS prenatal diagnosis major structural defect , 3 . Has enrol registry previous pregnancy , 4 . Has exposure know suspected human teratogen : Chlorambucil . Cyclophosphamide , Mycophenylate mofetil . For 'no chronic disease ' Prospective Cohort : 5 . Is &gt; 19 complete week gestation prior enrollment , 6 . Has first contact OTIS prenatal diagnosis major structural defect , 7 . Has enrol registry previous pregnancy , 8 . Has exposure know suspected human teratogen : Chlorambucil , Cyclophosphamide , Mycophenylate mofetil . Note : woman expose Entyvio pregnancy meeting criterion enroll Entyvio pregnancy exposure case series component registry .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>